🚚 Free shipping on all orders above $299 · 30 days money back guarantee · Helpline +1 251-332-4105

Tenofovir Alafenamide Taficita 200Mg /25Mg Tablets

$100.00$3.33 per tablet · 30 tablets
(3 customer reviews)
Choose pack sizePrice per tablet shown

Want to order in bulk / B2B price?

Tracked, discreet delivery

Ships in plain packaging with a tracking number. Delivery time for this product: 6 to 15 days. Free shipping on orders above $299.

30 days money back guarantee

Damaged, missing or only part of your order arrived? Choose a new package or a full refund.

Questions before you order?

Call +1 251-332-4105 or email [email protected].

SECURE CHECKOUT
DISCOVER
MasterCard
VISA

Share

Product verification: This description assumes Taficita 200 mg/25 mg contains emtricitabine 200 mg and tenofovir alafenamide 25 mg. Confirm both ingredients, their strengths, the manufacturer, and the product’s approved indications from its packaging and local prescribing information.

Important Safety Warning: Taficita contains two antiretroviral medicines. It is not a complete HIV treatment regimen when used alone. For HIV treatment, it must be combined with other appropriate antiretroviral medicines. In jurisdictions where this combination is approved for HIV prevention, it may be prescribed as pre-exposure prophylaxis (PrEP) only after confirming HIV-negative status and meeting other eligibility requirements.

People with hepatitis B virus (HBV) infection may experience serious hepatitis flare-ups after discontinuing emtricitabine/tenofovir alafenamide. Medical monitoring is essential.

What Is Taficita 200 mg/25 mg?

Taficita 200 mg/25 mg is a fixed-dose combination antiretroviral medicine containing emtricitabine and tenofovir alafenamide.

Both ingredients belong to the nucleoside/nucleotide reverse transcriptase inhibitor class.

They work by interfering with the HIV reverse transcriptase enzyme, which the virus needs to reproduce.

By inhibiting viral replication, these medicines help reduce the amount of HIV in the body when used as part of an effective combination antiretroviral treatment regimen.

Emtricitabine and tenofovir alafenamide are commonly used as the two-drug NRTI backbone of several HIV treatment regimens.

The same ingredient combination is also used for HIV pre-exposure prophylaxis in certain countries and populations, subject to regulatory approval and eligibility requirements.

Important: Taficita does not cure HIV infection. Effective treatment can suppress HIV replication and help maintain immune health, but ongoing medical care remains necessary.

How Does Taficita 200 mg/25 mg Work?

1. Combines Two Antiretroviral Ingredients

Taficita contains emtricitabine and tenofovir alafenamide, which target HIV replication through related mechanisms.

2. Inhibits HIV Reverse Transcriptase

HIV uses reverse transcriptase to convert its RNA into DNA during its replication cycle.

3. Emtricitabine Interferes With Viral DNA Synthesis

Emtricitabine is converted inside cells into its active phosphorylated form.

This active form competes with natural nucleotides and interrupts viral DNA synthesis.

4. Tenofovir Alafenamide Delivers Tenofovir

Tenofovir alafenamide is a prodrug that is converted inside cells to tenofovir and subsequently to its active form, tenofovir diphosphate.

5. Prevents Viral DNA Chain Extension

The active metabolites interfere with viral DNA synthesis and cause chain termination.

6. Reduces HIV Replication

When used with an appropriate complete HIV regimen, the combination helps suppress viral multiplication.

7. Supports Immune System Health

Sustained viral suppression can help preserve or restore CD4 T-cell counts and reduce HIV-related complications.

8. Provides a Foundation for Combination Therapy

Emtricitabine and tenofovir alafenamide are frequently paired with a third antiretroviral agent or other suitable medicines to form a complete HIV treatment regimen.

Important: These medicines do not eliminate latent HIV reservoirs and therefore do not cure HIV.

Uses of Taficita 200 mg/25 mg

1. HIV-1 Infection Treatment

Taficita may be used as part of a complete antiretroviral regimen for HIV-1 infection.

It must be combined with other appropriate antiretroviral medicines according to the prescribed treatment plan.

2. HIV Viral Load Suppression

The combination helps reduce HIV replication when used with an effective treatment regimen.

3. Supporting CD4 Cell Recovery

Effective antiretroviral treatment may help improve or preserve immune function.

Sustained HIV suppression reduces the risk of opportunistic infections and other HIV-related illnesses.

5. Long-Term HIV Management

The ingredients may form part of long-term antiretroviral therapy under specialist supervision.

6. Combination Antiretroviral Treatment

Emtricitabine and tenofovir alafenamide are commonly used with other antiretroviral agents.

7. HIV-1 Pre-Exposure Prophylaxis (PrEP)

In certain jurisdictions, emtricitabine 200 mg/tenofovir alafenamide 25 mg is approved for HIV-1 PrEP in eligible HIV-negative individuals.

However, this combination is not approved for HIV prevention in people at risk through receptive vaginal sex under the US reference labeling, because effectiveness for that exposure route has not been established.

Taficita’s own PrEP authorization must be verified locally.

8. Reducing the Risk of HIV Transmission During Treatment

When a person with HIV maintains a confirmed, sustained undetectable viral load through effective treatment, they do not sexually transmit HIV (Undetectable = Untransmittable, or U=U).

This benefit depends on sustained viral suppression, not on taking Taficita alone.

9. Maintaining Viral Suppression

The combination may be included in an appropriate regimen for patients who have achieved viral suppression.

10. Individualized Antiretroviral Therapy

A healthcare professional may select this combination based on treatment history, resistance testing, kidney function, hepatitis B status, and other clinical considerations.

Important: Taficita should not be promoted as a complete HIV treatment, a cure for HIV, or a universal HIV prevention medicine.

Taficita 200 mg/25 mg Dosage and Administration

The prescribed regimen depends on whether the medicine is being used for HIV treatment or an approved HIV prevention indication.

General Dosage Information

Dosage InformationDetails
Tablet StrengthEmtricitabine 200 mg + Tenofovir Alafenamide 25 mg
Common Adult FrequencyOne tablet once daily for the reference fixed-dose combination
Administration RouteOral
HIV TreatmentMust be combined with other appropriate antiretroviral medicines
PrEPOnly when approved and the patient meets eligibility requirements
Food InstructionsReference combination may be taken with or without food
Treatment DurationDetermined by the indication and healthcare professional
Kidney FunctionRequires assessment before and during treatment
Hepatitis B StatusMust be assessed because discontinuation may trigger hepatitis flare-ups
Medical SupervisionRequired

Important: The dosage above reflects commonly used reference prescribing information for emtricitabine/tenofovir alafenamide 200 mg/25 mg. The exact Taficita label and patient-specific instructions take precedence.

General Administration Instructions

  1. Take Taficita exactly as prescribed.
  2. Swallow the tablet whole with water.
  3. Take it at approximately the same time each day.
  4. Do not change the prescribed dose independently.
  5. Do not discontinue treatment without medical advice.
  6. If treating HIV, take the other prescribed antiretroviral medicines.
  7. Attend scheduled viral load and laboratory monitoring appointments.
  8. Inform the healthcare professional about all other medicines and supplements.
  9. Follow HIV testing requirements if prescribed for PrEP.
  10. Report significant side effects promptly.
  11. Inform the prescriber about hepatitis B infection.
  12. Maintain consistent treatment adherence.

Can Taficita Be Taken With Food?

The reference emtricitabine/tenofovir alafenamide 200 mg/25 mg combination may generally be taken with or without food.

Follow the product-specific instructions.

What If a Dose Is Missed?

Take the missed dose when remembered unless it is nearly time for the next scheduled dose.

Do not double the dose.

Contact the prescribing healthcare professional if multiple doses are missed or if there is uncertainty about the schedule.

Can Taficita Be Stopped Suddenly?

Do not discontinue Taficita without medical advice.

Stopping antiretroviral therapy may allow HIV viral load to increase.

Patients with hepatitis B infection may also experience serious hepatitis flare-ups after discontinuation.

Is Taficita a Complete HIV Treatment?

No.

Emtricitabine and tenofovir alafenamide are generally used with additional antiretroviral agents for HIV treatment.

Taking only these two ingredients to treat established HIV may result in inadequate viral suppression and drug resistance.

How Long Does Taficita Take to Work?

The active ingredients begin interfering with HIV replication after administration.

However, the time required to achieve viral suppression depends on the complete treatment regimen, baseline viral load, resistance profile, adherence, and individual response.

With effective combination antiretroviral therapy, HIV viral load commonly declines over the first several weeks.

Many patients achieve viral suppression within several months, although the timeline varies.

Healthcare professionals assess treatment effectiveness through HIV viral load testing rather than symptoms alone.

For PrEP, protection depends on the exposure route, adherence, and time taken to achieve protective drug concentrations. Patients should not assume immediate protection after the first dose.

Common Side Effects

Possible side effects include:

  • Headache
  • Nausea
  • Diarrhea
  • Fatigue
  • Abdominal discomfort
  • Mild gastrointestinal disturbances

Not every patient experiences these effects.

Side effects may also arise from other medicines used in the complete antiretroviral regimen.

Potentially Harmful Effects & Serious Health Risks

1. Hepatitis B Flare-Ups After Discontinuation

Patients with hepatitis B infection may develop severe worsening of hepatitis after stopping emtricitabine/tenofovir alafenamide.

2. Kidney Problems

Although tenofovir alafenamide generally has a more favorable renal safety profile than tenofovir disoproxil fumarate in comparative studies, kidney injury can still occur.

3. Fanconi Syndrome

Rare cases of proximal renal tubulopathy, including Fanconi syndrome, have been reported with tenofovir-containing medicines.

4. Lactic Acidosis

Rare but serious lactic acidosis has been associated with nucleoside/nucleotide analogue medicines.

5. Severe Liver Problems

Serious hepatomegaly with steatosis and other liver-related complications have been reported with medicines in this class.

6. Drug Resistance

Inadequate HIV treatment or use of PrEP during undiagnosed HIV infection may contribute to antiretroviral resistance.

7. HIV Infection During PrEP

PrEP substantially reduces HIV risk when used correctly but does not provide complete protection.

8. Reduced Effectiveness From Drug Interactions

Certain medicines may lower tenofovir alafenamide concentrations and reduce effectiveness.

9. Bone Health Concerns

Tenofovir alafenamide generally has less impact on bone mineral density than tenofovir disoproxil fumarate, but bone-related risks may still require assessment.

10. Immune Reconstitution Inflammatory Syndrome

Patients starting effective HIV treatment may develop inflammatory reactions to previously unrecognized or residual infections.

11. Severe Allergic Reactions

Hypersensitivity reactions may occur.

12. Treatment Failure

Poor adherence, drug interactions, or resistance may lead to inadequate viral suppression.

Emergency warning: Seek urgent medical attention for severe weakness, unusual breathing difficulties, persistent vomiting, significant abdominal pain, jaundice, markedly reduced urination, or symptoms suggesting serious liver or kidney injury.

Contraindications & Safety Precautions

1. Allergy to Active Ingredients

Do not take Taficita if allergic to emtricitabine, tenofovir alafenamide, or another formulation ingredient.

2. HIV Status Before PrEP

Patients must have confirmed HIV-negative status before starting PrEP.

Testing must also be repeated at recommended intervals during PrEP.

3. Acute HIV Infection

Starting PrEP during undiagnosed acute HIV infection may lead to drug resistance.

Symptoms of recent HIV infection should prompt appropriate testing.

4. Hepatitis B Infection

Patients should be assessed for hepatitis B before treatment because stopping the medicine may cause hepatitis flare-ups.

5. Kidney Disease

Kidney function should be assessed before treatment and monitored when clinically indicated.

6. Severe Renal Impairment

The reference emtricitabine/tenofovir alafenamide combination is generally not recommended for certain patients with creatinine clearance below 30 mL/min, with specific exceptions and restrictions depending on indication and dialysis status.

7. Liver Disease

Patients with liver disease require appropriate clinical assessment.

8. Pregnancy

Use during pregnancy requires individualized evaluation of maternal health, HIV treatment needs, and fetal safety.

9. Breastfeeding

Breastfeeding recommendations depend on HIV status, treatment indication, local guidance, and individual circumstances.

Patients should discuss this with their HIV specialist.

10. Children and Adolescents

Eligibility depends on age, body weight, indication, and local product approval.

11. Older Adults

Older adults may require additional kidney function monitoring and medication review.

12. HIV Drug Resistance

Resistance testing may influence treatment selection for patients with established HIV infection.

13. Adherence

Consistent dosing is essential for effective HIV treatment and PrEP.

14. Sexually Transmitted Infections

PrEP does not protect against other sexually transmitted infections such as syphilis, gonorrhea, or chlamydia.

15. Drug Interactions

Potentially important interactions include:

  • Rifampicin: May significantly reduce tenofovir alafenamide exposure.
  • Rifabutin and Rifapentine: May reduce tenofovir alafenamide concentrations.
  • Carbamazepine: May reduce tenofovir alafenamide exposure.
  • Phenytoin: May reduce tenofovir alafenamide exposure.
  • Phenobarbital: May reduce tenofovir alafenamide exposure.
  • Oxcarbazepine: May reduce tenofovir alafenamide exposure.
  • St. John’s Wort: May reduce tenofovir alafenamide concentrations.
  • Certain Antiviral Medicines: May cause overlapping toxicity or duplicate therapy.
  • Nephrotoxic Medicines: May increase kidney-related risks.

16. Duplicate Antiretroviral Ingredients

Patients should not combine Taficita with other medicines containing the same ingredients unless specifically directed by a specialist.

17. Medical Monitoring

Healthcare professionals may monitor:

  • HIV viral load
  • CD4 cell count when indicated
  • Kidney function
  • Serum creatinine
  • Estimated creatinine clearance
  • Urine glucose and protein when indicated
  • Hepatitis B status
  • Liver function
  • HIV resistance profile
  • Medication adherence
  • Drug interactions
  • Pregnancy status when relevant
  • Bone health when clinically indicated
  • HIV testing during PrEP
  • Sexually transmitted infection screening during PrEP

Advantages

  • Combines two established antiretroviral ingredients.
  • Once-daily administration in standard reference regimens.
  • Oral tablet formulation.
  • Supports effective combination HIV treatment.
  • Inhibits HIV reverse transcriptase.
  • May help reduce HIV viral load as part of complete therapy.
  • Supports long-term HIV management.
  • Used as an NRTI backbone in several regimens.
  • Tenofovir alafenamide generally has a more favorable renal and bone safety profile than tenofovir disoproxil fumarate.
  • May be used for PrEP in approved populations and jurisdictions.
  • Fixed-dose combination reduces the number of separate tablets required for these two ingredients.

Disadvantages / Limitations

  • Not a complete HIV treatment regimen when used alone.
  • Does not cure HIV.
  • Requires consistent adherence.
  • May cause nausea.
  • May cause headache.
  • May cause diarrhea.
  • May cause fatigue.
  • May cause kidney-related adverse effects.
  • Rarely associated with lactic acidosis.
  • Requires hepatitis B assessment.
  • Stopping treatment may cause hepatitis B flare-ups.
  • May interact with certain medicines.
  • Requires regular medical monitoring.
  • PrEP requires confirmed HIV-negative status.
  • PrEP does not prevent other sexually transmitted infections.
  • Not suitable for all HIV exposure routes under certain regulatory approvals.
  • May contribute to resistance if used inappropriately.
  • Requires caution in significant kidney impairment.
  • Pregnancy and breastfeeding require individualized assessment.
  • Product-specific approvals vary by country.

Important Notes

Brand Name: Taficita.

Generic Name: Emtricitabine + Tenofovir Alafenamide.

Strength: 200 mg/25 mg.

Drug Class: Nucleoside/Nucleotide Reverse Transcriptase Inhibitors.

Therapeutic Category: Antiretroviral / HIV Medicine.

Primary Use: HIV-1 treatment as part of a complete regimen.

Additional Use: HIV-1 PrEP where approved and appropriate.

Mechanism: Inhibition of HIV reverse transcriptase.

Administration Route: Oral.

Common Reference Frequency: Once daily.

Major Warning: Hepatitis B flare-ups after discontinuation, kidney toxicity, lactic acidosis, and potential drug resistance.

HIV Treatment Warning: Must be combined with other appropriate antiretroviral medicines.

PrEP Warning: Confirm HIV-negative status before starting and during treatment.

Pregnancy Warning: Requires individualized medical assessment.

Prescription Status: Prescription Medicine.

Storage: Follow manufacturer instructions.

Frequently Asked Questions

1. What is Taficita 200 mg/25 mg used for?

Taficita contains emtricitabine and tenofovir alafenamide. This combination is used as part of complete HIV-1 treatment regimens and may be used for PrEP where specifically approved.

2. What are the active ingredients in Taficita?

The stated ingredients are emtricitabine 200 mg and tenofovir alafenamide 25 mg.

3. Is Taficita an HIV medicine?

Yes. It contains two antiretroviral ingredients that inhibit HIV reverse transcriptase.

4. Can Taficita cure HIV?

No. It can help suppress HIV replication as part of effective treatment, but it does not cure HIV.

5. Is Taficita a complete HIV treatment?

No. For established HIV infection, emtricitabine/tenofovir alafenamide must be combined with other appropriate antiretroviral medicines.

6. Can Taficita be used for HIV prevention?

The ingredient combination is approved for PrEP in certain jurisdictions and eligible populations. Taficita’s specific approval must be confirmed.

7. Can Taficita prevent HIV from every type of sexual exposure?

No. Under US reference labeling, emtricitabine/tenofovir alafenamide PrEP is not approved for people at risk through receptive vaginal sex because effectiveness for that exposure route has not been established.

8. How does Taficita work?

Its active ingredients inhibit HIV reverse transcriptase, interfering with viral DNA synthesis and replication.

Product DetailsInformation
Product NameTaficita 200 mg/25 mg Tablets
Brand NameTaficita
Generic NameEmtricitabine + Tenofovir Alafenamide
Active Ingredient 1Emtricitabine 200 mg
Active Ingredient 2Tenofovir Alafenamide 25 mg
Dosage FormOral Film-Coated Tablet (verify packaging)
Drug ClassNucleoside/Nucleotide Reverse Transcriptase Inhibitors (NRTIs)
Therapeutic CategoryAntiretroviral / HIV Medicine
Primary UseHIV-1 treatment as part of a complete antiretroviral regimen
Additional UseHIV-1 pre-exposure prophylaxis (PrEP), where specifically approved and prescribed
Mechanism of ActionInhibition of HIV reverse transcriptase
Administration RouteOral
ManufacturerVerify from product packaging
Pack SizeVerify from product packaging
Prescription StatusPrescription Medicine
StorageFollow manufacturer instructions; protect from moisture and excessive heat
Pack sizes30 tablets, 60 tablets, 90 tablets, 120 tablets, 150 tablets, 300 tablets

3 reviews for Tenofovir Alafenamide Taficita 200Mg /25Mg Tablets

  1. Klarissa Smith (verified owner) –

    Boosted my confidence, noticeable difference!

  2. Richard Withrow (verified owner) –

    Increased pleasure, amazing stamina boost!

  3. Deborah Carl (verified owner) –

    Natural ingredients, great effects, no side effects!

Add a review

Your email address will not be published. Required fields are marked *

Bulk / B2B price inquiry

Tell us what you need and we’ll reply by email.